Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from DENTSPLY SIRONA ( (XRAY) ) is now available.
On November 25, 2025, DENTSPLY SIRONA Inc. announced the appointment of Michael Pomeroy as interim Chief Financial Officer. Pomeroy, with extensive experience in finance leadership across various industries, will support the company’s President and CEO, Daniel T. Scavilla, until a permanent CFO is appointed. This strategic appointment aims to leverage Pomeroy’s expertise in growth, turnaround, and operational improvement to strengthen the company’s financial leadership during the transition period.
The most recent analyst rating on (XRAY) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
Spark’s Take on XRAY Stock
According to Spark, TipRanks’ AI Analyst, XRAY is a Neutral.
DENTSPLY SIRONA’s overall stock score reflects significant financial and technical challenges. The company’s financial performance is weak, with declining revenues, negative profitability, and liquidity issues. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold indicators. The valuation is also concerning, with a negative P/E ratio, although the high dividend yield provides some appeal. The company’s strategic challenges and focus on a turnaround plan add to the uncertainty.
To see Spark’s full report on XRAY stock, click here.
More about DENTSPLY SIRONA
Average Trading Volume: 3,460,883
Technical Sentiment Signal: Sell
Current Market Cap: $2.14B
See more insights into XRAY stock on TipRanks’ Stock Analysis page.